Navigation Links
Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
Date:10/22/2008

tes, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
6. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Avicena Group to Present at Noble Financial Conference
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
(Date:12/19/2014)... iLab Solutions, the global leader in core facility ... the new Director of Institutional Implementations and Sarah Becker ... new leadership positions were created to support iLab’s mission ... continues to meet the needs of its growing customer ... been deployed at over 450 core facilities across more ...
(Date:12/19/2014)... 18, 2014 Egenix, Inc. is pleased to announce ... of the Board, to succeed Donald Fresne ; Mr. ... continue as a member of the Board.  In recognition of ... the company over almost twenty years, the Board designated Mr. ... Directors has established a Search Committee to find a suitable ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... France, May 6 Pierre Fabre Dermatologie,specialised department ... the,launch of a set of clinical trials following ... on July 10th 2008 with the University of,Bordeaux. ... of a,paediatric beta-blocker for the treatment of severe ...
... Dendreon Corporation (Nasdaq: DNDN ) today reported results for ... first quarter of 2009 was $30,000 compared to $31,000 for the ... the three months ended March 31, 2009 were $17.0 million compared ... net loss for the quarter ended March 31, 2009 was $15.4 ...
... measure cardiopulmonary gas exchange in heart failure patients. It can ... Kocheril, Professor of Medicine and Director of Clinical Electrophysiology at ... ... Minneapolis-St. Paul, MN (PRWEB) May 6, 2009 -- ...
Cached Biology Technology:Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma 2Dendreon Reports First Quarter 2009 Financial Results 2Dendreon Reports First Quarter 2009 Financial Results 3Dendreon Reports First Quarter 2009 Financial Results 4Dendreon Reports First Quarter 2009 Financial Results 5University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System 2University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System 3University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System 4
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... Many people know Edward Teller as the "Father of the ... War. To his detractors he was evil personified. Between these extremes ... is a serious, well researched attempt to interpret the enigmatic nature ... up for his beliefs," says G. A. Keyworth, II, science advisor ...
... can substitute rice hulls for perlite in their media ... according to a Purdue University study. Growing media ... of peat and perlite, a processed mineral used to ... ensure consistent and desired plant characteristics such as height ...
... new assessment of future scenarios that limit the extent ... R&D portfolios for the development of new, efficient, and ... reduction targets are unlikely to be met, or met ... efficiency as the single most important option for achieving ...
Cached Biology News:'Judging Edward Teller' 2'Judging Edward Teller' 3Rice hulls a sustainable drainage option for greenhouse growers 2Changes in energy R&D needed to combat climate change 2Changes in energy R&D needed to combat climate change 3
... Useful for the mechanical harvesting of ... and ensures even contact with the growth ... and 75cm flasks • Individually wrapped • ... Linkage: This CLS number is a new ...
... The MagneGST™ Protein Purification System ... method for the purification of glutathione-S-transferase ... particles (MagneGST™ Particles) are used to ... crude or cleared lysate using either ...
... compact, versatile system that simultaneously harvests and ... microplates into a solid filter supports for ... gamma counter. The FilterMate is ideal for ... as cell proliferation, receptor binding, nucleic acid ...
... screening project: , 384 Individual ... shape-diverse mixtures of 4 (5 uL each) , ... Individual compounds are dissolved in DMSO at ca. ... Supplied in 5 96-well trays. Dilute library with protein ...
Biology Products: